A Compliant, Safe Approach to Addressing High-Cost Medications and Pharmacy Costs

This is how the Pharmacy Stewardship Program® operates legally and compliantly.

The Pharmacy Stewardship Program® begins with a narrow and defined problem. In most self funded health plans, a very small percentage of medications drives a disproportionate share of total pharmacy spend. The program is built to address that specific area through a data first sourcing process that reviews lawful pathways to determine the lowest net cost option for a medication while maintaining clinical continuity and fitting within the client’s existing plan design. Depending on the drug and the situation, those pathways may include domestic discount channels, patient assistance programs, foundation support, and international sourcing. 

Its legal structure starts with the basic federal standards that govern drug safety and quality. Under federal law, the central question is not simply whether a drug comes from outside the United States. The real questions are whether it was manufactured in conformity with current Good Manufacturing Practice, whether it is properly labeled, and whether it would satisfy FDA import review. The PSP® is structured around those standards. It relies on sourcing pathways that are evaluated for Good Manufacturing Practice alignment, proper labeling, prescription support, pharmacy licensure, chain of custody controls, shipment integrity, fulfillment reliability, and documentation sufficient for review.  

That matters because federal law treats safety and legality as process questions. A drug is considered adulterated if it is not manufactured under the required Good Manufacturing Practice controls, and it is considered misbranded if the labeling is false, misleading, or incomplete. FDA then has authority to examine imported drugs and refuse admission if they appear adulterated, misbranded, or otherwise noncompliant. In other words, the program operates within a framework where manufacturing compliance, labeling integrity, dispensing controls, and import review are the governing issues.  

The PSP® also operates compliantly by distinguishing personal use importation from commercial drug distribution. That distinction is essential. The program is built around patient specific prescriptions, quantities limited to an individual course of treatment, direct shipment to the individual, and the absence of resale. When those conditions are present, and when the medication is manufactured in conformity with Good Manufacturing Practice, properly labeled, and dispensed pursuant to a valid prescription, the arrangement fits within the import review framework applied to personal use rather than the rules governing bulk commercial distribution. 

The statutory framework also matters here. Congress addressed importation authority in 21 U.S.C. § 384 and specifically recognized defined conditions for personal use importation. The file explains that this includes conditions such as importation from a licensed pharmacy for personal use, not for resale, in quantities that do not exceed a 90 day supply, accompanied by a valid prescription, with final dosage manufactured in a registered establishment, and under any additional conditions needed for public safety. The PSP® is designed around those parameters, with operational attention to whether the activity is personal use rather than commercial introduction into interstate commerce. 

Legal compliance is only one layer. The program also addresses the fact that the domestic international sourcing market is uneven. The file states that there are more than 20 vendors in this space with differing levels of structure, documentation, and regulatory discipline, and that some have received FDA warning letters. That is why the PSP® does not treat all vendors as interchangeable. Through the proprietary C PSP certification framework, vendors are evaluated against objective criteria, including Good Manufacturing Practice alignment in sourcing jurisdictions, countries recognized by FDA as having comparable regulatory systems, international pharmacy licensure and standing, documented chain of custody, shipment integrity controls, transparent pricing methodology, fulfillment performance standards, and documentation sufficient to support fiduciary review. Vendors that do not meet those standards are excluded from the network.  

The program also operates compliantly from an ERISA standpoint. Self funded employer health plans are subject to fiduciary duties under ERISA, and the prudence standard is process driven. The file explains that courts examine whether fiduciaries engaged in a reasoned and documented review of plan expenditures, vendor arrangements, and cost structures. Pharmacy benefit arrangements fall within that scrutiny when they affect plan assets and participant cost sharing. The PSP® addresses this by starting with claims level analysis, documenting cost concentration, evaluating lawful alternatives, producing formal bid comparisons, and creating a written record of review and decision making. That process is intended to show that high cost pharmacy spend was not simply accepted without scrutiny and that lower cost lawful options were actually evaluated.  

Operationally, that means the program is not just a sourcing arrangement. It is a structured governance model. Limitless certifies and filters the market through its C PSP framework, uses aggregate volume to negotiate preferred pricing within that network, runs claims level analytics across sourcing channels, performs competitive bid review, documents the fiduciary analysis, coordinates implementation, and provides subject matter expertise on international sourcing compliance when requested. The file also states that Limitless compensation is incorporated within negotiated pricing structures so that clients do not incur additional program costs beyond realized savings. 

Stated plainly, this is how the PSP® operates legally and compliantly: it uses lawful sourcing pathways, applies federal manufacturing and labeling standards, works within the distinction between personal use and commercial distribution, filters vendors through objective compliance criteria, documents chain of custody and prescription support, subjects the opportunity to competitive pricing review, and creates a fiduciary record showing that concentrated pharmacy spend was evaluated with care, skill, prudence, and diligence. That is the operating model.